Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST)
<strong>Objective</strong> Report results from PERSIST, a real-life, observational, prospective cohort study of CT-P13, an infliximab (IFX) biosimilar, for treatment of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis (PsA) who were biologic-naï...
Hoofdauteurs: | Taylor, PC, Christensen, R, Moosavi, S, Selema, P, Guilatco, R, Fowler, H, Mueller, M, Liau, KF, Haraoui, B |
---|---|
Formaat: | Journal article |
Taal: | English |
Gepubliceerd in: |
British Society for Rheumatology
2021
|
Gelijkaardige items
-
Real-world safety data from patients with rheumatic diseases treated with CT-P13, an infliximab biosimilar: an interim analysis from an observational study
door: Taylor, P, et al.
Gepubliceerd in: (2019) -
“Treat to Persist”, una profundización del “Treat to Target”
door: Gustavo Citera, et al.
Gepubliceerd in: (2020-06-01) -
Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review
door: Anghel LA, et al.
Gepubliceerd in: (2018-07-01) -
Persistent Subretinal Fluid: Wait or Treat?
door: Ertugrul Tan Yassa, et al.
Gepubliceerd in: (2018-08-01) -
Persistent post-stroke dysphagia treated with cricopharyngeal myotomy
door: Sruthi S Nair, et al.
Gepubliceerd in: (2016-01-01)